Addressing modifiable risk factors for anticoagulant-related bleeding in patients with cancer is an effective way to reduce bleeding and enable these patients to continue anticoagulant therapy, according to the results of a recently presented study at the 66th ASH Annual Meeting & Exposition held in San Diego, CA.
Read More ›
